Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1
The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru
New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is
Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,
Novo Nordisk’s obesity drug isn’t even available in the UK yet, but the government has already launched a pilot programme that could see access to the drug expanded throug